Table 2.

Univariate and multivariate analysis of predictors of PFS in the chemoimmunotherapy cohort

Parameters	Univariate analysis HR (95% CI)	P-value	Multivariate analysis HR (95% CI)	P-value
Age ≥ 70 years	1.04 (0.50–2.14)	0.92
Sex, female	1.46 (0.59–3.62)	0.41
ECOG-PS ≥ 1	3.73 (1.66–8.38)	0.0014	2.80 (1.12–6.99)	0.028
HLA I high	0.97 (0.47–2.00)	0.94
CD8-high	0.34 (0.16–0.73)	0.0060	0.29 (0.12–0.70)	0.0061
Subtype SCLC-N (vs SCLC-I)	4.14 (0.90–19.07)	0.068	3.13 (0.63–15.57)	0.16
Subtype SCLC-P (vs SCLC-I)	7.41 (1.17–47.02)	0.037	10.77 (1.15–101.00)	0.037
Subtype SCLC-A (vs SCLC-I)	2.53 (0.75–8.60)	0.14	1.53 (0.43–5.36)	0.51
C-Stage ≥ IVB	2.30 (0.93–5.64)	0.070	2.93 (1.03–8.32)	0.043
Presence of severe irAE	0.70 (0.21–2.34)	0.57

CI confidence interval, HR hazard ratio